How Principal Investigators Can Proactively Improve Patient Enrollment
Failure to enroll enough patients is one of the primary reasons clinical trials fail. Direct mail, advertising and social media…
Moving From Health Disparity to Health Equity: Addressing Social Determinants of Health to Improve CKD Outcomes
Socioeconomic status influences chronic kidney disease (CKD) risk. Socioeconomic disparities intertwine with racial, geographic and health care disparities. One result:…
Activating Clinical Trial Sites Quickly During COVID-19 Lockdowns
A sponsor needed to enroll at least 200 patients for a pivotal Phase IIIb clinical trial — right when the…
By the Numbers: Optimize Sites for Your Nephrology-Related Trials With Frenova
See how Frenova’s impact on CKD and ESRD clinical trials compares to industry averages. The numbers don’t lie: our clinical…
Disruptive Changes for a Better Clinical Research Future
While the SARS-CoV-2 (COVID-19) pandemic has been terrible in terms of morbidity and mortality, it did show the promise of…
Frenova Empowers Investigators and Research Teams
Why Frenova? As a Fresenius Medical Care company, Frenova manages the world’s largest network of renal research assets: over 550…
Increase Revenue and Give Patients More Options With Clinical Trials: Five Things to Consider When Adding or Expanding Research at Your Practice
Adding clinical research is a business strategy that, if approached knowledgably, can be of great benefit to physicians and medical…
How Do You Keep Your Trials Moving Forward When Patients Can’t Come to Your Office? FRENOVA KNOWS
Learn how Frenova is helping sites continue clinical research during the COVID-19 pandemic.
How Do You Keep Studies Progressing When The World Stands Still?
Learn what Frenova has been doing to keep studies on track during the COVID-19 pandemic.
Missed Revenue in Clinical Research: 1 Study, 10 Sites, $154,000 Caught
Whether from faulty sponsor payment systems, incomplete invoicing, or other causes, private practice investigational sites routinely miss out on significant…